OmniAb, Inc. (OABI): Capital Expenditures
$565.0K
Year ended 2025-12-31
$468.0K
Trailing 12 months to 2026-06-30
-68.0%
3-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $565.0K | -69.9% | 2026-03-04, From 2025-01-01 |
| 2024-12-31 | $1.88M | +14.1% | 2026-03-04, From 2024-01-01 |
| 2023-12-31 | $1.64M | -90.4% | 2025-03-18, From 2023-01-01 |
| 2022-12-31 | $17.17M | +321.8% | 2024-03-25, From 2022-01-01 |
| 2021-12-31 | $4.07M | n/a | 2023-03-30, From 2021-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| OmniAb, Inc. (OABI) | 2025-12-31 | $565.0K | -69.9% |
| Foxo Technologies Inc. (FOXO) | 2025-12-31 | $62.0K | n/a |
| MaxCyte, Inc. (MXCT) | 2025-12-31 | $1.77M | +7.1% |
| bioAffinity Technologies, Inc. (BIAF) | 2025-12-31 | $60.6K | -23.4% |
| Absci Corp (ABSI) | 2025-12-31 | $1.11M | +174.0% |
| NRC Health (NRC) | 2025-12-31 | $10.71M | -30.7% |
| iSpecimen Inc. (ISPC) | 2025-12-31 | $454 | -98.6% |
| OneMedNet Corp (ONMD) | 2025-12-31 | $13.0K | -74.5% |
| Medpace Holdings, Inc. (MEDP) | 2025-12-31 | $31.36M | -14.2% |
Compare OABI, FOXO, MXCT, BIAF side by side · Screen every company in Services-Commercial Physical & Biological Research ↗